RE:Reschedule isn’t legalizationThe biggest news for Canopy is them completing the deal with Acreage A and B US MSO that will allow Canopy to rapidly launch all of the tried and true brands they developed in Canada for the world.
The USA is the most promising market for profits from all of the marijuana and hemp skus, especially the pharma ones.
Rescheduling opens the door for more scientific research on cannabinoids for the US and International concerns.
Canopy lined up Acreage while Constellation got a hook in to some vey good brands at very good prices that they want to vend in to CUSA to get a path to being able to touch the product and be a player on US soil.
Full Federal legalization for pharma and adult rec use is what I am looking for as an investor and the deals I have mentioned is Klein's plan to bring this home as a US MSO.
Joining all of these together makes Canopy formidable again in the US marketplace.